ACB
Aurora Cannabis Inc.
ACB's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ACB overall, supported by stronger fundamentals and lower modeled downside.
ACB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ACB's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACB PE Valuation
ACB has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect ACB's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.36 | -500% |
| Q1 2026 | -$0.91 | -2375% |
| Q4 2025 | -$0.53 | -431% |
| Q3 2025 | -$0.14 | +$0.47 |
| Q2 2025 | $0.34 | +$0.80 |
| Q1 2025 | $0.04 | +$1.18 |
| Q4 2024 | $0.16 | +$2.37 |
| Q3 2024 | -$0.61 | +$2.63 |
ACB has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ACB on earnings quality, reporting a profit while its opponent remains loss making.
ACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $47.5M | -23% |
| Q1 2026 | $26.8M | -58% |
| Q4 2025 | $66.2M | +6.8% |
| Q3 2025 | $63.5M | +11% |
| Q2 2025 | $62M | +5.7% |
| Q1 2025 | $63.7M | +34% |
| Q4 2024 | $62M | +37% |
| Q3 2024 | $57M | +29% |
ACB's revenue is shrinking: $48M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -70% | -112 points |
| Q1 2026 | -66% | -33 points |
| Q4 2025 | 5.1% | -37 points |
| Q3 2025 | -20% | -17 points |
| Q2 2025 | 42% | +41 points |
| Q1 2025 | -34% | -38 points |
| Q4 2024 | 42% | +69 points |
| Q3 2024 | -3% | +14 points |
ACB's operating margin was −70% last quarter, down 112 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ACB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ACB on profitability, with a higher operating margin.
ACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -294% |
| Q1 2026 | -$3.8M | -$3.4M |
| Q4 2025 | $7.7M | -54% |
| Q3 2025 | -$32.9M | -$12.2M |
| Q2 2025 | $3.6M | +58% |
| Q1 2025 | -$438K | +$18.4M |
| Q4 2024 | $16.9M | +$22.5M |
| Q3 2024 | -$20.7M | +$4M |
ACB has burned cash in most quarters: −$36M over the past year, against −$702,335 the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ACB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +4.2M shares |
| 1 year | +11% | +5.9M shares |
| 3 years | +74% | +26.3M shares |
| 5 years | +212% | +41.9M shares |
| Available history | +612% | +53M shares |
ACB has 62M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ACB hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ACB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ACB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -4.5x | Net Cash |
| Q2 2024 | -5.2x | Net Cash |
| Q4 2023 | -0.2x | Net Cash |
ACB has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 84.8 | Overbought |
ACB's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ACB PE vs Healthcare Sector
| Metric | ACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.33 | 15% above |
| 20 week MA | $3.72 | 34% above |
| 50 week MA | $3.73 | 34% above |
| 100 week MA | $4.26 | 17% above |
| 200 week MA | $5.00 | 0.2% below |
ACB has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 0.2% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ACB on trend strength, trading above more of its moving averages.
ACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $229.2 | $88.7 | -61% |
| 2021 | $88.7 | $61.2 | -31% |
| 2022 | $61.2 | $9.27 | -85% |
| 2023 | $9.27 | $4.76 | -49% |
| 2024 | $4.76 | $4.30 | -9.7% |
| 2025 | $4.30 | $4.49 | +4.4% |
| 2026 YTD | $4.49 | $4.99 | +11% |
ACB has finished lower in five of the last six years. It's up 11% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ACB on returns for 2026, with the stronger performance.